Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of TG Therapeutics, Inc. (NASDAQ: TGTX) (“TG Therapeutics”) securities.
On August 1, 2023, TG Therapeutics announced its financial results for the second quarter and reported a net loss of $47.6 million and $86.8 million for the three and six months ended June 30, 2023, compared to $40.5 million and $109.5 million for the three and six months ended June 30, 2022. Additionally, TG Therapeutics revealed that its highly anticipated multiple sclerosis drug, “Briumvi,” which launched in the U.S. in late January, missed analysts' consensus expectations of nearly $17.5 million, generating only $16.1 million in U.S. drug sales.
Following this news, the price of TG Therapeutics’ stock declined by nearly 50%, to close at $10.49 per share on August 1, 2023.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com.